Synairgen Stock Soars 420% On Promise Of Inhaled COVID-19 Drug
Small Study Excites Investors
Preliminary results show that hospitalized coronavirus patients who received Synairgen's inhaled interferon beta product had a 79% lower risk of developing severe disease compared with placebo.
You may also be interested in...
Disappointment as Roche/Chugai antibody tocilizumab misses most endpoints.
The coronavirus research field may be dominated by vaccines from the likes of Oxford University/AstraZeneca and Pfizer/BioNTech, but a lot of interesting work is being done elsewhere by smaller academic and commercial projects looking at the potential of various novel antibody therapies against COVID-19.
More studies are being launched into possible treatments for patients hospitalised with COVID-19, with Roche launching a Phase III, placebo-controlled trial of Actemra.